President Trump signed an executive order Saturday directing federal agencies to conduct a speedy review of psychedelic drugs, including ibogaine, marking a potential shift in U.S. drug policy.

The executive order comes as data indicates changing patterns in recreational drug use among Americans, particularly younger generations. Recent studies show cocaine use has declined significantly among Generation Z compared to previous generations, while interest in psychedelic substances appears to be growing.

Cocaine became widely popular as a party drug in the United States beginning in the early 1970s, initially emerging through Miami. The drug's widespread use contributed to the federal government's "war on drugs" policy, which has shaped American drug enforcement for decades.

Ibogaine, one of the substances mentioned in Trump's order, is a psychoactive compound derived from the African plant Tabernanthe iboga. The substance has drawn attention from researchers studying its potential therapeutic applications, particularly for treating addiction disorders.

The executive order does not specify what form the review will take or what potential policy changes might result. Federal agencies including the Drug Enforcement Administration and Food and Drug Administration would likely be involved in any comprehensive evaluation of psychedelic substances' legal status and medical potential.